Avalo Therapeutics Inc

NASDAQ:AVTX   3:59:52 PM EDT
0.31
-0.01 (-4.51%)
Earnings Announcements

Avalo Therapeutics Executed Workforce Reduction To Align With Previously Announced Pipeline Prioritization

Published: 05/05/2022 13:04 GMT
Avalo Therapeutics Inc (AVTX) - Avalo Therapeutics Inc- Executed Workforce Reduction to Align With Previously Announced Pipeline Prioritization.
Avalo Therapeutics Inc- Reaffirms Milestone Timing for Phase 2 Clinical Trial of Avtx-002 in Nea and Pivotal Trial of Avtx-803 in Lad Ii.
Avalo Therapeutics Inc - Qtrly Loss per Share $0.20.
Avalo Therapeutics - As of March 31, Avalo Had $38.5 Million in Cash and Cash Equivalents, Representing $16.1 Million Decrease As Compared to Dec 31, 2021.
Avalo Therapeutics Inc- Expects Salary Related Expenses to Decrease Beginning in Q2 As a Result of Headcount Reductions.
Revenue is expected to be $0.99 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $0.79 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.